Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.62 |
| ▸ | IGF1R | P08069 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20574578 | 0.90 | EGFR (0.63) | EGFRIGF1RKCNH2 | |
| SCHEMBL18921777 | 0.89 | EGFR (0.61) | EGFRIGF1RKCNH2 | |
| SCHEMBL20574032 | 0.89 | EGFR (0.65) | EGFRIGF1RKCNH2 | |
| SCHEMBL19239592 | 0.87 | EGFR (0.82) | EGFRIGF1RKCNH2 | |
| SCHEMBL20574575 | 0.85 | EGFR (0.58) | EGFRIGF1RKCNH2 | |
| SCHEMBL18369580 | 0.84 | EGFR (0.83) | EGFRIGF1RKCNH2 | |
| SCHEMBL20574580 | 0.84 | EGFR (0.58) | EGFRIGF1RKCNH2 | |
| SCHEMBL18921733 | 0.79 | EGFR (0.61) | EGFRIGF1RKCNH2 | |
| SCHEMBL19239591 | 0.78 | EGFR (0.74) | EGFR | |
| SCHEMBL19860194 | 0.78 | EGFR (0.77) | EGFRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383877-B1 | HETEROCYCLE COMPOUNDS AND USES THEREOF | ZHEJIANG JIANFENG YIEN BIOTECHNOLOGY CO LTD (CN) | 2021-09-15 | — | — | EP | claimed |
| US-10844074-B2 | Heterocycle compounds and uses thereof | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. (CN) | 2020-11-24 | — | — | US | claimed |
| US-20180346479-A1 | HETEROCYCLE COMPOUNDS AND USES THEREOF | SHANGHAI AEON BIOTECH CO., LTD. (CN) | 2018-12-06 | — | — | US | claimed |
| EP-3383877-B1 | HETEROCYCLE COMPOUNDS AND USES THEREOF | ZHEJIANG JIANFENG YIEN BIOTECHNOLOGY CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| US-10844074-B2 | Heterocycle compounds and uses thereof | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-10844074-B2 | Heterocycle compounds and uses thereof | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20180346479-A1 | HETEROCYCLE COMPOUNDS AND USES THEREOF | SHANGHAI AEON BIOTECH CO., LTD. (CN) | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844074-B2 | Heterocycle compounds and uses thereof | BTK, ITK, JAK3 | EGFR 7/4885IGF1R 206/4885KCNH2 3178/4885 |
| US-20180346479-A1 | HETEROCYCLE COMPOUNDS AND USES THEREOF | BTK, ITK, JAK3 | EGFR 7/4885IGF1R 206/4885KCNH2 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.